Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
Hallucinogen |
| gptkbp:bindingTarget |
gptkb:5-HT1A_receptor
gptkb:sigma-1_receptor 5-HT2A receptor |
| gptkbp:boilingPoint |
160 °C (at 0.5 mmHg)
|
| gptkbp:CASNumber |
61-50-7
|
| gptkbp:category |
alkaloid
Hallucinogen serotonin receptor agonist |
| gptkbp:chemicalFormula |
C12H16N2
|
| gptkbp:color |
white to yellow crystalline solid
|
| gptkbp:discoveredBy |
gptkb:Richard_Helmuth_Fredrick_Manske
|
| gptkbp:discoveredIn |
1931
|
| gptkbp:effect |
mystical experiences
euphoria visual hallucinations 5–30 minutes (inhaled) 2–6 hours (oral with MAOI) altered perception of time |
| gptkbp:featuredIn |
book 'DMT: The Spirit Molecule' by Rick Strassman
|
| gptkbp:foundIn |
gptkb:Ayahuasca
|
| gptkbp:hasInChIKey |
KXANITVJZQZKSG-UHFFFAOYSA-N
|
| gptkbp:hasSMILES |
CN(C)CCc1c[nH]c2cccc(C1)2
|
| https://www.w3.org/2000/01/rdf-schema#label |
N,N-Dimethyltryptamine
|
| gptkbp:IUPACName |
2-(1H-indol-3-yl)-N,N-dimethylethanamine
|
| gptkbp:legalStatus |
gptkb:Schedule_III_(Canada)
gptkb:Schedule_I_(US) gptkb:Class_A_(UK) Schedule 9 (Australia) |
| gptkbp:mainStreet |
gptkb:DMT
the spirit molecule |
| gptkbp:meltingPoint |
44–46 °C
|
| gptkbp:metabolism |
gptkb:monoamine_oxidase
|
| gptkbp:molecularWeight |
188.27 g/mol
|
| gptkbp:naturalOccurrence |
some animals
various plants human body (trace amounts) |
| gptkbp:PubChem_CID |
gptkb:CHEMBL39122
6089 CHEBI:4610 |
| gptkbp:relatedTo |
gptkb:5-MeO-DMT
gptkb:bufotenin psilocybin serotonin |
| gptkbp:routeOfAdministration |
inhalation
intramuscular injection oral (with MAOI) |
| gptkbp:solubility |
slightly soluble in water
soluble in ethanol soluble in chloroform |
| gptkbp:toxicity |
low acute toxicity
|
| gptkbp:UNII |
WUB6018FEM
|
| gptkbp:usedIn |
spiritual practices
shamanic rituals |
| gptkbp:bfsParent |
gptkb:DMT
|
| gptkbp:bfsLayer |
7
|